Navigation Links
Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeutics, Inc. announced today that its small molecule portfolio of apoptosis-triggering compounds will be featured in three oral presentations and several poster presentations at next week's 2007 Annual Meeting of the American Association for Cancer Research (AACR), to be held in Los Angeles, California April 14-18, 2007.

Ascenta's MDM2 program has been selected for presentation at the "High Impact Late-Breaking Research 1" session on Tuesday, April 17 (Hall A at 3:30pm) and will be presented by Dajun Yang, MD, PhD, Senior Vice President of Research at Ascenta Therapeutics and General Manager of Ascenta's R&D Subsidiary in Shanghai, China. The MDM2 program will also be featured in a talk on Saturday, April 14 (Petree D at 4:15pm) by University of Michigan's Professor Shaomeng Wang, PhD, a co-founder of Ascenta.

Preclinical studies of AT-101, Ascenta's clinical stage, oral pan-Bcl-2 inhibitor, will be featured in an oral presentation by Dr. Yang on Wednesday, April 18 and in several poster presentations authored by Ascenta personnel and collaborating investigators. In a collaboration with scientists at Human Genome Sciences, Inc., studies of HGSI's TRAIL receptor agonist monoclonal antibodies in combination with Ascenta's small molecule XIAP inhibitors, will be presented in a poster session on Tuesday, April 17 (1pm-5pm). The full schedule of presentations featuring Ascenta's technology is as follows: -0-

Date      Time      Title                              Presenter,

                                                        Collaborator

--------- --------- ---------------------------------- --------------

Saturday  4:15pm    Potent, specific, non-peptidic     Shaomeng Wang,

April 14             small molecule inhibitors of the   PhD, U.

                     Human MDM2-p53 interaction as a    Michigan

                     new class of anticancer therapy

--------- --------- --------
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... to its store . (Photo: ... of population, consumption upgrade and policy support, ... seen rapid development over the years, with total ... 2006 to 9.85 billion yuan in 2012. ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, ... and contracting company, awarded several new IT value-added ... to provide hospital organizations with IT goods and ... and service agreements, as well as value-added services ... support. New Novation agreements were ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ... Pharmaceutical Industries Ltd (NYSE: TEVA ) and ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... International (OTC Bulletin Board: SNDZ ) said ... for glaucoma and ocular hypertension, is making its mark ... Trading Co. Ltd. (BVW), in 2007, the PNT treatment ... gaining regulatory approval by China,s Federal Drug Administration earlier ...
... and eCardio Diagnostics, one of the leading providers ... of mobile technology with cardiac care to provide ... is providing eCardio with machine-to-machine (M2M) ... remote monitoring of cardiac patients. eCardio,s monitoring solution ...
Cached Medicine Technology:Sunridge Advances its PNT Glaucoma Treatment Throughout China 2AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 2AT&T and eCardio Diagnostics Team Up to Advance Cardiac Care Through Innovative Mobile Technology 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... , , , ... AMLN ) today reported financial results for the quarter ended June 30, ... ended June 30, 2009, which includes net product sales of $197.5 million. ... sales force reduction in the second quarter, was $51.0 million, or $0.36 ...
... , , , , ... the second quarter of fiscal 2009 on Thursday, August 6, 2009. , ... hosted by management at 11 a.m. ET following distribution of the earnings release. ... , in the News Room on the day of the earnings announcement. ...
... ... ... 1-800-731-5774, ... PRINCETON, NJ, July 21 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. invites analysts and investors to participate in a briefing on ...
... three cases of likely HIV transmission to infants via pre-chewed food ... - chewing food; also a need for more ... Researchers have uncovered the first cases in which HIV almost ... The source of HIV in the pre-chewed food was most likely the infected ...
... , MEQUON, Wis., July 21 Wonderbox ... its clients to benefit from continued advances in technology and ... Management Module designed for managed care benefit administration and case ... tools for scheduling, managing, and monitoring day-to-day care tasks and ...
... diagnose disease early, study shows, , TUESDAY, July 21 ... may accurately identify the people with mild cognitive impairment ... new study finds. , Changes in the chemistry of ... Alzheimer,s disease. If and when treatments are available for ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 12Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results 2Health News:Pre-chewed Food Could Transmit HIV 2Health News:Pre-chewed Food Could Transmit HIV 3Health News:Pre-chewed Food Could Transmit HIV 4Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2Health News:Biomarkers May Predict Alzheimer's 2Health News:Biomarkers May Predict Alzheimer's 3
The STAAR ELASTIMIDE™ lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
Foldable Silicone Multi-piece Lens....
... The PhacoFlexII SI30NB is foldable ... to it's patients. It is ... The SI30NB is indicated for ... correction of aphakia in adults ...
Liberty Three Piece PMMA Lens with UV Absorber....
Medicine Products: